Research map: JMB2403, a potential best-in-class PD-1-dependent IL2Rβγ-activating tri-specific antibody for safe and potent immunotherapy

Back to the article

Papers in this map

  1. Reshaping human antibodies for therapy · Lutz Riechmann · 1988 · 1568 citations · Cited by this paper
  2. Antibody framework engineering enables augmented cytokine receptor signaling capacities of bispecific single domain antibody-based IL-21 mimetics · Britta Lipinski · 2026 · Cites this paper
  3. NAStructuralDB : structural database to facilitate computational studies of molecular modeling and recognition of proteins with special focus on antibody–antigen interactions · 2026 · Related
  4. Replacing the complementarity-determining regions in a human antibody with those from a mouse · Peter Jones · 1986 · 1423 citations · Cited by this paper
  5. Engineering of acidic pH-responsive anti-CD3 binding antibodies · 2026 · Related
  6. NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models · Deborah H. Charych · 2016 · 407 citations · Cited by this paper
  7. Structure-based calculation of excipient effects on the viscosity of concentrated antibody solutions · 2026 · Related
  8. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo · Aran F. Labrijn · 2009 · 296 citations · Cited by this paper
  9. Balancing the extremes for antibody developability: hydrophobic and electrostatic germline framework signatures for CDR-loop compensation · 2026 · Related
  10. The Shared and Contrasting Roles of IL2 and IL15 in the Life and Death of Normal and Neoplastic Lymphocytes: Implications for Cancer Therapy · Thomas A. Waldmann · 2015 · 244 citations · Cited by this paper
  11. Efficient inference of non-polyreactive antibody variants dependent on local fine-tuning · 2026 · Related
  12. A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors · Salah-Eddine Bentebibel · 2019 · 236 citations · Cited by this paper
  13. ASD: antigen-specific antibody database · 2026 · Related
  14. A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases · Miro E. Raeber · 2023 · 195 citations · Cited by this paper
  15. Expanding the horizons of cancer therapy with next-generation 4-1BB agonists: a review of molecular and clinical strategies to maximize efficacy and ensure safety · 2026 · Related
  16. Interleukin-2 signaling in the regulation of T cell biology in autoimmunity and cancer · Acacia N. Shouse · 2024 · 154 citations · Cited by this paper
  17. AbDist: a lightweight, distance-based model for antibody affinity prediction as an interpretable benchmark for machine learning models · 2026 · Related
  18. Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis · Shixue Chen · 2021 · 135 citations · Cited by this paper
  19. Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8+ T cells and reprogramming macrophages · Mélanie Tichet · 2023 · 134 citations · Cited by this paper
  20. Facile discovery of surrogate cytokine agonists · Michelle Yen · 2022 · 87 citations · Cited by this paper
  21. IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells · Weiwei Wu · 2023 · 80 citations · Cited by this paper
  22. IL-2 based cancer immunotherapies: an evolving paradigm · Sushama Rokade · 2024 · 79 citations · Cited by this paper
  23. Fine-tuned long-acting interleukin-2 superkine potentiates durable immune responses in mice and non-human primate · Rosemina Merchant · 2022 · 60 citations · Cited by this paper
  24. Phase I Trial of BAY 50-4798, an Interleukin-2–Specific Agonist in Advanced Melanoma and Renal Cancer · Kim Allyson Margolin · 2007 · 57 citations · Cited by this paper
  25. Approaches for the detection and analysis of antidrug antibodies to biopharmaceuticals: A review · Kyungah Suh · 2022 · 46 citations · Cited by this paper
  26. A bispecific antibody agonist of the IL-2 heterodimeric receptor preferentially promotes in vivo expansion of CD8 and NK cells · Katherine E. Harris · 2021 · 43 citations · Cited by this paper
  27. Interleukin 2-Based Fusion Proteins for the Treatment of Cancer · Alana MacDonald · 2021 · 42 citations · Cited by this paper
  28. Generation and engineering of potent single domain antibody-based bispecific IL-18 mimetics resistant to IL-18BP decoy receptor inhibition · Britta Lipinski · 2023 · 31 citations · Cited by this paper
  29. i-shaped antibody engineering enables conformational tuning of biotherapeutic receptor agonists · Matthew G. Romei · 2024 · 22 citations · Cited by this paper
  30. A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351 · Chunyin Gu · 2021 · 20 citations · Cited by this paper
  31. Taming interleukin‐12: Engineering of bispecific antibody‐based IL ‐12 mimetics with biased agonism capacities · Britta Lipinski · 2025 · 14 citations · Cited by this paper
  32. How GRAIL controls Treg function to maintain self-tolerance · C. Garrison Fathman · 2022 · 12 citations · Cited by this paper
  33. AWT020: a novel fusion protein harnessing PD-1 blockade and selective IL-2 Cis-activation for enhanced anti-tumor immunity and diminished toxicity · Fan Ye · 2025 · 10 citations · Cited by this paper
  34. ANV600 is a novel PD-1 targeted IL-2Rβγ agonist that selectively expands tumor antigen-specific T cells and potentiates PD-1 checkpoint inhibitor therapy · Patrizia Murer · 2025 · 10 citations · Cited by this paper
  35. Advanced cytokine-based immunotherapies: targeted cis-delivery strategies for enhanced anti-tumor efficacy and reduced toxicity · Laurène Pousse · 2025 · 6 citations · Cited by this paper
  36. Abstract CT259: Results from monotherapy dose escalation of MDNA11, a long-acting IL-2 superkine, in a phase 1/2 trial show evidence of single-agent activity in advanced solid tumors · Victoria G. Atkinson · 2024 · 6 citations · Cited by this paper
  37. A novel dual mechanism-of-action bispecific PD-1-IL-2v armed by a “βγ-only” interleukin-2 variant · Yongji Jiang · 2024 · 5 citations · Cited by this paper
  38. Structure-Guided Stapling of Dimeric Conformations and Linker Engineering Enhance Thermostability and Fine-Tune Activity of Bispecific VHH Cytokine Agonists · Raphael Trenker · 2025 · 4 citations · Cited by this paper
  39. Multifunctional antibody-derived IL-12 mimetics: prospects of future clinical development · Britta Lipinski · 2026 · 4 citations · Cited by this paper

Source: OpenAlex (CC0)